CLINICAL TRIAL AGREEMENTClinical Trial Agreement • July 9th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations • California
This Clinical Trial Agreement (“Agreement”) is made as of the 29th day of April, 2010 (“Effective Date”) between Putney Drug Corp., a Nevada corporation, having a principal place of business at 3930 Varsity Drive, Ann Arbor, MI 48109 (“Company”), and The Regents of the University of California, a constitutional California corporation, on behalf of its Los Angeles campus, with an address at David Geffen School of Medicine UCLA Clinical Trials Contracts Unit, 10911 Weyburn Avenue, 3rd Floor, Los Angeles, CA 90095-7170 (“Institution”), each referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO CLINICAL TRIAL AGREEMENTClinical Trial Agreement • July 9th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations
This Amendment To Clinical Trial Agreement (the "CTA Amendment") is made and entered into effective as of July 8, 2015 (the "CTA Amendment Effective Date") by and between Putney Drug Corp., a Nevada corporation having a place of business at 617 Detroit Street, Suite 100, Ann Arbor, MI, 48104 ("Company"), and The Regents of the University of California, a constitutional California corporation, on behalf of its Los Angeles campus, with an address at David Geffen School of Medicine UCLA Clinical Trials Administration Office, 10911 Weybeurn Avenue, 3rd Floor, Los Angeles California 90095-7170 ("Institution" or "The Regents"), to amend the terms of that certain Clinical Trial Agreement between Company and Institution, originally dated as of April 29, 2010 (the "CTA"). Company and Institution may be referred to herein individually as a "Party", and collectively as the "Parties".
FIFTH AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2006-04-0026The License Agreement • July 9th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations
THIS FIFTH AMENDMENT (the “Fifth Amendment”), dated July 25, 2014 (the “Effective Date”), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA(“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and PUTNEY DRUG CORP. (“Licensee”) having a principal place of business at 155 Gibbs Street, Suite 412, Rockville, MD 20850 amends the Exclusive License Agreement ,dated June 11 2005, between the Licensee and The Regents with UC Agreement Control No. 2006-04-0026 and subsequent amendments (collectively, the “License Agreement”) in accordance with the terms and conditions of this Fifth Amendment.
SIXTH AMENDMENT TO THE LICENSE AGREEMENT UC Control No. 2006-04-0026License Agreement • July 9th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations
THIS SIXTH AMENDMENT (the “Sixth Amendment”), dated July 8, 2015, (the “Sixth Amendment Effective Date”), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles, located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 (the “Institution”), and PUTNEY DRUG CORP. (“Licensee”), having a principal place of business at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104, and amends the Exclusive License Agreement, dated June 11, 2005, between Licensee and The Regents with UC Agreement Control No. 2006-04-0026 (the “Original License Agreement”) and subsequent amendments thereto (collectively, the “License Agreement”) in accordance with the terms and conditions of this Sixth Amendment. The Regents and Licensee may be referred to herein individu
